Company profile
InoCardia - Cardiac Contractility
Inocardia Limited is a UK company with status active founded in 2013 based in West Midlands.
Financial period: 1 Oct 2023 to 30 Sep 2024
Reference milestones and recent Companies House filing stream events.
CS01 | Transaction MzUyOTgyMDA0M2FkaXF6a2N4
Published 02 Jul 2026 11:57
Next confirmation statement due date
TM01 | Transaction MzUyOTgxMjMyNGFkaXF6a2N4
Published 01 Jul 2026 10:02
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Mar 2021 to 31 Mar 2022
As the founder of InoCardia Ltd, I have applied 30 years' experience aligned to the pharmaceutical industry to commercialise the cardiac Work-Loop contractility platform as a spin-out company from Coventry University in 2013\. The commercialisation of my academic research started with a vision that there was a fundamental need within the Pharmaceutical In...
1 Jun 2020 to 28 Feb 2021
Returning to a 'normally' functioning global society post COVID-19 will require effective drugs and vaccines, particularly if we are unable to develop long-term immunity to the virus. Hospital studies have shown us that COVID-19 weakens the heart, leading to more severe consequences, so we must ensure that the new drugs we develop to fight COVID-19 do not...
1 May 2017 to 31 Jan 2019
When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people. This is a significant risk to human health & is costly to th...
1 May 2016 to 31 Mar 2020
When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people. This is a significant risk to human health & is costly to th...
1 Aug 2014 to 30 Apr 2016
When drugs are developed to treat a particular disease they sometimes have side effects that cause damage to to the heart. Occasionally these dangerous side effects are only recognised after the drug has been marketed and thousands of patients have been treated. This is a significant risk to human health and causes very high costs to the pharmaceutical in...
1 Jul 2014 to 31 Mar 2016
Adverse effect of drugs on the cardiovascular system is a major cause for compounds failing in both non-clinical and clinical studies. Indeed, some of these adverse effects may only be currently detected after the compound has been granted marketing approval and many thousands of patients treated. Thus such effects represent a significant issue for human ...
